Download
https://www.ndtvprofit.com/business/biocon-slips-as-earnings-miss-estimates-on-delayed-approvals-for-drugs?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
Revenue for the quarter also saw a drop of 2.2 percent over the year-ago period.
Share